The greater superficial petrosal nerve is unnecessary for normal responsiveness to sucrose by rats in a brief-access test, regardless of trial length

Appetite ◽  
2008 ◽  
Vol 51 (2) ◽  
pp. 354
Author(s):  
G.D. Blonde ◽  
Y. Treesukosol ◽  
E. Jiang ◽  
A.C. Spector
Keyword(s):  
Trial Length ◽  
Greater Superficial Petrosal Nerve ◽  
Access Test

scholarly journals Excision of Greater Superficial Petrosal Nerve Schwannoma Via a Pure Endoscopic Endonasal Approach

2021 ◽  
pp. 014556132110263
Author(s):  
Zhenlin Wang ◽  
Siyuan Zhang ◽  
Yan Qi ◽  
Lianjie Cao ◽  
Pu Li ◽  
...  
Keyword(s):  
Hearing Loss ◽  
Clinical Features ◽  
Middle Cranial Fossa ◽  
Nerve Sheath Tumor ◽  
Endoscopic Endonasal Approach ◽  
Endonasal Approach ◽  
Endoscopic Endonasal ◽  
Greater Superficial Petrosal Nerve ◽  
Clinical Records

Greater superficial petrosal nerve (GSPN) schwannomas are an exceedingly rare nerve sheath tumor. The current literature search was conducted using Medline and Embase database by key search terms. Only 31 cases have been reported in the literature so far. Facial palsy, hearing loss, and xerophthalmia accounted for 48.4% (15), 41.9% (13), and 29% (9) of all cases, respectively. The middle cranial fossa approach was used in all previous reports. A retrospective review of 2 GSPN schwannomas patients treated by endoscopic endonasal approach (EEA) in our center was collected. Clinical records, including clinical features, pre- and postoperative images, surgery, and follow-up information, were reviewed. In all cases, clinical features including facial numbness and headache were found, with tinnitus in case 1, hearing loss, xerophthalmia in case 2. Imaging studies showed a solid mass that originated in the anterior of the petrous bone. Two patients were treated by EEA. Furthermore, no recurrence was found during the follow-up period (15-29 months) in both of the 2 cases after the operation. Complete resection of GSPN schwannomas can be achieved via the pure EEA. Endoscopic endonasal approach for radical removal of tumors is safe and feasible.

Greater superficial petrosal nerve schwannoma

2005 ◽  
Vol 147 (6) ◽  
pp. 659-663 ◽  
Author(s):  
A. Schmidinger ◽  
W. Deinsberger
Keyword(s):  
Greater Superficial Petrosal Nerve

scholarly journals Factors Contributing Spinal Cord Stimulator Explantation

Neurosurgery ◽  
2019 ◽  
Vol 66 (Supplement_1) ◽  
Author(s):  
Francisco A Ponce ◽  
Dakota Graham ◽  
Margaret Lambert ◽  
Zaman Mirzadeh
Keyword(s):  
Spinal Cord ◽  
Chronic Pain ◽  
Patient Selection ◽  
Failed Back Surgery Syndrome ◽  
Trial Duration ◽  
Trial Length ◽  
Common Diagnosis ◽  
Failed Back Surgery ◽  
Surgical History ◽  
Permanent Implant

Abstract INTRODUCTION Spinal cord stimulation (SCS) is commonly used to treat various forms of chronic pain. For some patient, the initial benefit is short lived and they return for device removal. The aims of this study are to identify reasons for SCS explantation and to analyze the circumstances of implantation to identify improvement opportunities for appropriate patient selection and prediction of successful clinical response to the therapy. METHODS This is a retrospective review of 178 patients who underwent SCS explantation over the past 9 yr. RESULTS The most common reason for explantation was a lack of efficacy. Of the 178 patients that received explantation, 141 (79%) indicated that lack of efficacy played a role, 31 (17%) discomfort, 20 (11%) side effects, 22 (12.4%) infection, and 24 (13.5%) expressed the need for an MRI. More than one factor prompted explantation for 33% of these patients (n = 58). A diagnosis of various types of chronic pain without failed back surgery syndrome (FBSS) was the most common diagnosis made up 63% (n = 72/115) of explants, while patients with FBSS made up 37% (n = 43/115). The average SCS trial duration of patients receiving explants was 5.016 d. When comparing the average duration of a permanent SCS implant with the length of a SCS trial, a shorter trial length corresponded with a longer permanent implant duration. SCS trials lasting less than and greater than or equal to five days resulted in an average permanent implant duration of 36.5 mo (n = 25) and 20 mo (n = 38), respectively (alpha = 0.05, P = .0166). CONCLUSION Identifying opportunities for more appropriate patient selection for SCS will increase success rate of the therapy and reduce the number of explants. This may be possible through closer consideration of pain presentation and surgical history, as well as a re-evaluation of trialing methods for SCS.

scholarly journals Prospective Evaluation of the mariPOC Test for Detection of Clostridioides difficile Glutamate Dehydrogenase and Toxins A/B

2020 ◽  
Vol 58 (4) ◽  
Author(s):  
Roosa Savolainen ◽  
Juha M. Koskinen ◽  
Silja Mentula ◽  
Janne O. Koskinen ◽  
Suvi-Sirkku Kaukoranta
Keyword(s):  
Glutamate Dehydrogenase ◽  
Random Access ◽  
Pcr Assay ◽  
Toxin A ◽  
Predictive Values ◽  
Content Type ◽  
Clostridioides Difficile ◽  
Membrane Enzyme ◽  
Access Test ◽  
B Test

ABSTRACT The objective of this study was to evaluate a novel automated random-access test, mariPOC CDI (ArcDia Ltd., Finland), for the detection of Clostridioides difficile glutamate dehydrogenase (GDH) and toxins A and B directly from fecal specimens. The mariPOC test was compared with both the GenomEra C. difficile PCR assay (Abacus Diagnostica Oy, Finland) and the TechLab C. diff Quik Chek Complete (Alere Inc.; now Abbot) membrane enzyme immunoassay (MEIA). Culture and the Xpert C. difficile assay (Cepheid Inc., USA) were used to resolve discrepant results. In total, 337 specimens were tested with the mariPOC CDI test and GenomEra PCR. Of these specimens, 157 were also tested with the TechLab MEIA. The sensitivity of the mariPOC test for GDH was slightly lower (95.2%) than that obtained with the TechLab assay (100.0%), but no toxin-positive cases were missed. The sensitivity of the mariPOC test for the detection of toxigenic C. difficile by analyzing toxin expression was better (81.6%) than that of the TechLab assay (71.1%). The analytical specificities for the mariPOC and the TechLab tests were 98.3% and 100.0% for GDH and 100.0% and 99.2% for toxin A/B, respectively. The analytical specificity of the GenomEra method was 100.0%. The mariPOC and TechLab GDH tests and GenomEra PCR had high negative predictive values of 99.3%, 98.3%, and 99.7%, respectively, in excluding infection with toxigenic C. difficile. The mariPOC toxin A/B test and GenomEra PCR had an identical analytical positive predictive value of 100%, providing highly reliable information about toxin expression and the presence of toxin genes, respectively.

Schwannoma of the Greater Superficial Petrosal Nerve: An Unusual Site for a Common Tumor

2020 ◽  
Vol 81 (06) ◽  
pp. 565-570
Author(s):  
Alok Mohan Uppar ◽  
Shilpa Rao ◽  
Chandrajit Prasad ◽  
Arivazhagan Arimappamagan ◽  
Vani Santosh
Keyword(s):  
Facial Nerve ◽  
Rare Case ◽  
Literature Search ◽  
English Literature ◽  
Clinical Spectrum ◽  
Small Subset ◽  
Rare Clinical Entity ◽  
Review Of The Literature ◽  
Unusual Site ◽  
Greater Superficial Petrosal Nerve

AbstractGreater superficial petrosal nerve (GSPN) schwannoma is a rare clinical entity. It forms a small subset of the larger group of facial nerve schwannomas. A thorough literature search yielded only 27 such cases reported to date in the English literature. We present one such rare case of GSPN schwannoma and discuss the clinical spectrum and management along with a review of the literature. We demonstrate the surgical steps in an operative video.

CELLULAR SCHWANNOMA OF THE GREATER SUPERFICIAL PETROSAL NERVE PRESENTING WITH ABDUCENS NERVE PALSY AND XEROPHTHALMIA

Neurosurgery ◽  
2008 ◽  
Vol 63 (4) ◽  
pp. E813-E814 ◽  
Author(s):  
Giyas Ayberk ◽  
Mehmet F. Ozveren ◽  
Nuket Uzum ◽  
Ozgur Tosun ◽  
Emine K. Akcay
Keyword(s):  
Nerve Palsy ◽  
Abducens Nerve ◽  
Abducens Nerve Palsy ◽  
Petrous Apex ◽  
Clinical Prognosis ◽  
Tear Secretion ◽  
Pathological Evaluation ◽  
Greater Superficial Petrosal Nerve ◽  
Extradural Approach ◽  
The Right

ABSTRACT OBJECTIVE Cellular schwannomas (CS) are rare in the cranial space. This report is the first of a patient with a greater superficial petrosal nerve CS presenting with abducens nerve palsy and xerophthalmia. CLINICAL PRESENTATION A 16-year-old female patient presented with a 1-month history of diplopia. Neurological examination was normal except for the presence of right abducens nerve palsy. Schirmer's test revealed decreased tear secretion in the right eye. Computed tomography and magnetic resonance imaging showed a mass in the right petrous apex. It was thought that the schwannoma in our patient originated from the greater superficial petrosal nerve, based on the location of the tumor in addition to the absence of partial Horner's syndrome and a persistent decrease in tear secretion. INTERVENTION: The tumor was exposed with the use of a right subtemporal extradural approach and removed entirely. Pathological evaluation of the tumor revealed a CS. CONCLUSION The abducens nerve palsy improved completely in the follow-up period, but the decreased tear secretion did not resolve. CS is one of the subtypes of ordinary schwannomas and exhibits malignant features on microscopic examination, although it has a good clinical prognosis. No adjuvant treatment was applied because of the tumor's benign character. The greater superficial petrosal nerve schwannoma should be considered in the differential diagnosis of the abducens nerve palsy and petrous apex mass.

Vasodilator system for the face

1975 ◽  
Vol 42 (6) ◽  
pp. 696-703 ◽  
Author(s):  
Guillermo Gonzalez ◽  
Burton M. Onofrio ◽  
Frederick W. L. Kerr
Keyword(s):  
Brain Stem ◽  
Trigeminal Ganglion ◽  
Content Type ◽  
Moderate Number ◽  
Trigeminal Nuclei ◽  
The Face ◽  
Greater Superficial Petrosal Nerve ◽  
Radiofrequency Coagulation ◽  
The Brain ◽  
Stimulation Of

✓ The authors describe investigations in cats to delineate a vasodilator system to the face, which they undertook after a previous study showed that radiofrequency coagulation of the trigeminal ganglion produced a pronounced flush in the skin of the corresponding division. Results demonstrate a vasodilator system emerging from the brain stem with the facial nerve which, by way of the greater superficial petrosal nerve, reaches the trigeminal ganglion. There the fibers are distributed to each of the divisions of the fifth nerve; in addition, a moderate number of vasodilator fibers also appear to leave the brain stem directly with the trigeminal nerve. Vasodilator effects were elicited by stereotaxic stimulation of the facial and trigeminal nuclei in the brain stem. There is, therefore, a dual vasomotor control of the facial cutaneous vascular bed; the classical sympathetic vasoconstrictor system of the face is complemented by a vasodilator system capable of producing changes of equal but opposite amplitude in vessel caliber.

Sign in / Sign up

Export Citation Format

Share Document